Moderna Patent Settlement With Genevant And Arbutus
Moderna patent settlement ends global LNP litigation; a $950M upfront charge trims 2026 cash outlook and leaves a $1.3B contingent payout tied to an appeal.
KEY TAKEAWAYS
- Moderna agreed to a $2.25 billion settlement resolving global LNP litigation.
- A $950 million upfront payment narrows Moderna's 2026 cash outlook to $4.5-$5.0 billion.
- A $1.3 billion contingent payout depends on the Federal Circuit Section 1498 appeal outcome.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Moderna, Inc. resolved global litigation with Genevant Sciences and Arbutus Biopharma on March 3, 2026, over lipid-nanoparticle delivery technology used in its Spikevax COVID-19 vaccine. The settlement will prompt a first-quarter charge that narrows Moderna’s 2026 cash outlook and sets the stage for an appeal under Section 1498, which limits government contractor liability.
Settlement Terms and Licenses
The $2.25 billion agreement includes a $950 million noncontingent upfront payment due by July 8, 2026, and a $1.3 billion contingent payment payable if an appellate court rules that Section 1498 does not bar claims except for doses supplied to U.S. government employees. The deal directs the court to enter judgments of infringement and no invalidity on four patents held by Genevant and Arbutus.
Genevant grants Moderna a global, non-exclusive, royalty-free, and irrevocable license to its lipid-nanoparticle technology for SM-102-containing mRNA vaccines targeting infectious diseases. The companies also agreed to covenants not to sue on specified patents and products. The settlement extinguishes future royalty claims related to Spikevax, mRESVIA, mNEXSPIKE, mCOMBRIAX, and Moderna’s broader infectious-disease vaccine pipeline.
The Pfizer/BioNTech litigation over similar technology remains active in U.S. District Court following a September 2025 Markman ruling favorable to Genevant and Arbutus. Comirnaty, Pfizer/BioNTech’s vaccine, accounts for about two-thirds of global COVID-mRNA vaccine sales to date.
James Heyes, chief executive of Genevant Sciences, said, "We are pleased with this settlement, which allows us to put this lengthy dispute behind us."
Cash Outlook and Appeals
Moderna projects year-end 2026 cash and cash equivalents of $4.5 billion to $5.0 billion, reflecting the first-quarter charge for the upfront payment. The company did not accrue the contingent payment, judging a loss on that item not probable. Arbutus is considering a return of capital to shareholders in the third quarter of 2026, linked to receipt of the upfront payment.
Moderna will appeal the Delaware district-court ruling to the Federal Circuit and plans to assert limited government-contractor liability under Section 1498. The contingent payment depends on the appellate outcome.
Arbutus filed a Current Report on Form 8-K on March 3, 2026, disclosing the settlement terms. Roivant Sciences, Genevant’s parent company, also filed a Form 8-K and issued a press release at 4:15 p.m. ET that day. Roivant hosted an investor call at 4:45 p.m. ET.
